2022
DOI: 10.31744/einstein_journal/2022ao5587
|View full text |Cite
|
Sign up to set email alerts
|

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats

Abstract: Objective: To evaluate the effects of combining topiramate, bupropion and naltrexone in obesity-induced rats on their weight and subcutaneous adipose tissue. Methods: A total of 40 male Wistar rats were induced to obesity for 8 weeks and the animals were divided into 8 groups: Ctr - control, G0 - Sham, G1 - oral saline solution (1.0mL/day), G2 - topiramate (20.0mg/kg) and bupropion (5.0mg/kg), G3 - naltrexone (20.0mg/kg), G4 - topiramate (20.0mg/kg), G5 - bupropion (5.0… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 11 publications
0
0
0
Order By: Relevance
“…Topiramate is currently used in the treatment of epilepsy and migraines since it is an α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/kainate (AMPA/KA) glutamate receptor antagonist. Topiramate has a GABAergic mechanism of action but it is also an anorexigenic and is currently used for the treatment of obesity [124].…”
Section: Phentermine/topiramatementioning
confidence: 99%
“…Topiramate is currently used in the treatment of epilepsy and migraines since it is an α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/kainate (AMPA/KA) glutamate receptor antagonist. Topiramate has a GABAergic mechanism of action but it is also an anorexigenic and is currently used for the treatment of obesity [124].…”
Section: Phentermine/topiramatementioning
confidence: 99%